Syndax Pharmaceuticals SNDX announced positive top-line results for revumenib, an oral small-molecule menin inhibitor, from the AUGMENT-101 study. The results were announced from the relapsed or ...

USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – As many biotech companies within the oncology space begin to roll out their ...

Syndax (SNDX) announced positive topline results from the relapsed or refractory mutant NPM1 – mNPM1 – acute myeloid leukemia ...

Edward White, an analyst from H.C. Wainwright, reiterated the Buy rating on Syndax Pharmaceuticals (SNDX – Research Report). The ...

Syndax Pharmaceuticals (Nasdaq: SNDX) has announced that its Phase II AUGMENT-101 trial of experimental drug revumenib ...

Syndax Pharmaceuticals advances Revumenib for relapsed AML with FDA decision pending. See why SNDX stock is a key player in ...

Syndax Pharmaceuticals' experimental drug revumenib achieved 23% complete remission in NPM1-mutated acute myeloid leukemia ...

On Tuesday, Syndax Pharmaceuticals Inc (NASDAQ:SNDX) revealed topline results from the relapsed or refractory (R/R) mutant ...

(RTTNews) - Syndax Pharmaceuticals, Inc. (SNDX), Tuesday announced positive results from the relapsed or refractory mutant NPM1 acute myeloid leukemia cohort in the pivotal Phase 2 portion of the ...

While awaiting an FDA decision for its small molecule revumenib in one form of acute leukemia, Syndax Pharmaceuticals is ...

Despite the promising data, Syndax Pharmaceuticals saw its stock plummet by -21.49% in premarket trading after the latest update on its AUGMENT-101 trial. As of Tuesday morning, the stock was trading ...

Syndax Pharmaceuticals (SNDX) stock dropped ~23% after the company posted Phase 2 trial data for its AML candidate, revumenib ...